Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Selected Articles from This Issue

DOI:  Published October 2020
  • Article
  • Info & Metrics
  • PDF
Loading

Amivantamab Induces EGFR/cMet Downmodulation By Trogocytosis

Vijayaraghavan et al. Page 2044

Amivantamab (JNJ-61186372) is an EGFR/cMet bispecific low fucose antibody that recently received breakthrough therapy designation and is being testing clinically in NSLC patients. In this preclinical study, Vijayaraghavan and colleagues demonstrated that interaction of the Fc domain of amivantamab with monocytes or macrophages induces trogocytosis leading to EGFR and cMet receptor downmodulation and tumor cell death. In addition, they found that macrophages were required for amivantamab anti-tumor efficacy in vivo. Thus, this represents a novel Fc-dependent mechanism of action for amivantamab, and highlights trogocytosis as a key mechanism to exploit in designing new antibody-based cancer therapies.

Mechanisms of Antitumor Activity of Novel USP7 Inhibitors

Ohol et al. Page 1970

The deubiquitinase USP7 stabilizes the expression of multiple substrates important in tumor progression, such as MDM2, PIM2 kinase, and MYCN. Therefore, potent inhibitors of USP7 are highly desired. Ohol and colleagues report selective inhibitors of USP7 which impede its binding to ubiquitin and tested the inhibitors on a panel of 430 cancer cell lines. Several TP53 wild-type and a subset of TP53 mutant cell lines were sensitive to USP7 inhibition. Inhibition led to increased levels of p53 in TP53 wild-type cells and upregulated genes repressed by the EZH2-containing PRC2 complex in TP53 mutant cells. In vivo, USP7 inhibition inhibited the growth of TP53 wild-type multiple myeloma tumors as well as TP53 mutant small cell lung cancer tumors. Their results demonstrate USP7 inhibitor candidates viable for continued mechanistic studies and clinical translation.

Antiandrogens Promote the Effects of Radiotherapy in GBM

Werner et al. Page 2163

The androgen receptor (AR) is more highly expressed in glioblastoma (GBM) than in normal brain. Since AR signaling mediates radiation resistance in prostate cancer – as well as other cancers – and radiation resistance is a significant barrier to GBM treatment, we decided to utilize antiandrogens as a radiosensitizing strategy in GBM models. Antiandrogens inhibited the growth of and radiosensitized AR-positive cell lines and patient-derived xenografts. They also delayed repair of radiation-induced DNA damage and blocked adaptive transcriptional programs. Overall, the combination of blood-brain barrier permeable antiandrogens with radiation may represent a promising strategy for the treatment of AR-positive GBMs.

Tumor Mutational Burden and Overall Survival

Riviere et al. Page 2139

High tumor mutational burden is correlated with positive responses to immune checkpoint blockade. Here, Riviere and colleagues determine if TMB serves as an independent prognostic marker in immunotherapy-naïve patients. They outline the parabolic nature of the TMB relationship to overall survival, wherein patients with low or high mutations trend higher survival times while those with intermediate TMB trend lower. As no patients had received immunotherapy, these results demonstrate TMB as a prognostic indicator that is independent of immunotherapy. Potential mediators of the lower overall survival in intermediate TMB patients are discussed and are a pertinent focus for future studies.

  • ©2020 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 19 (10)
October 2020
Volume 19, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Selected Articles from This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Selected Articles from This Issue
Mol Cancer Ther October 1 2020 (19) (10) 1957;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Selected Articles from This Issue
Mol Cancer Ther October 1 2020 (19) (10) 1957;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Amivantamab Induces EGFR/cMet Downmodulation By Trogocytosis
    • Mechanisms of Antitumor Activity of Novel USP7 Inhibitors
    • Antiandrogens Promote the Effects of Radiotherapy in GBM
    • Tumor Mutational Burden and Overall Survival
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement